AVIDITY BIOSCIENCES INC (RNA)
US05370A1088 - Common Stock
Taking everything into account, RNA scores 4 out of 10 in our fundamental rating. RNA was compared to 568 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for RNA as it has an excellent financial health rating, but there are worries on the profitability. RNA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
RNA had negative earnings in the past year.
In the past year RNA has reported a negative cash flow from operations.
RNA had negative earnings in each of the past 5 years.
In the past 5 years RNA reported 4 times negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -17.09%, RNA is in the better half of the industry, outperforming 79.82% of the companies in the same industry.
The Return On Equity of RNA (-18.66%) is better than 86.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.09% | ||
| ROE | -18.66% | ||
| ROIC | N/A |
ROA(3y)-29.53%
ROA(5y)-25.48%
ROE(3y)-34.47%
ROE(5y)-30.71%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RNA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
RNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
RNA has more shares outstanding than it did 1 year ago.
RNA has more shares outstanding than it did 5 years ago.
There is no outstanding debt for RNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 15.98 indicates that RNA is not in any danger for bankruptcy at the moment.
RNA has a better Altman-Z score (15.98) than 90.80% of its industry peers.
RNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 15.98 |
ROIC/WACCN/A
WACC11.91%
2.3 Liquidity
RNA has a Current Ratio of 17.76. This indicates that RNA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of RNA (17.76) is better than 93.10% of its industry peers.
A Quick Ratio of 17.76 indicates that RNA has no problem at all paying its short term obligations.
RNA has a Quick ratio of 17.76. This is amongst the best in the industry. RNA outperforms 93.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 17.76 | ||
| Quick Ratio | 17.76 |
3. Growth
3.1 Past
RNA shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.68%.
RNA shows a decrease in Revenue. In the last year, the revenue decreased by -0.23%.
The Revenue has been growing by 90.61% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)3.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.45%
Revenue 1Y (TTM)-0.23%
Revenue growth 3Y12.08%
Revenue growth 5Y90.61%
Sales Q2Q%-17.1%
3.2 Future
RNA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.06% yearly.
RNA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 119.67% yearly.
EPS Next Y3.39%
EPS Next 2Y-5.06%
EPS Next 3Y-4.25%
EPS Next 5Y25.06%
Revenue Next Year-51.7%
Revenue Next 2Y-27.75%
Revenue Next 3Y48.26%
Revenue Next 5Y119.67%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for RNA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RNA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as RNA's earnings are expected to decrease with -4.25% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.06%
EPS Next 3Y-4.25%
5. Dividend
5.1 Amount
RNA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AVIDITY BIOSCIENCES INC
NASDAQ:RNA (12/20/2024, 8:00:01 PM)
After market: 31.82 0 (0%)31.82
+0.77 (+2.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners96.66%
Inst Owner Change11.54%
Ins Owners0.69%
Ins Owner Change11.79%
Market Cap3.80B
Analysts83.75
Price Target69.79 (119.33%)
Short Float %13.29%
Short Ratio14.19
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.1%
Min EPS beat(2)9.54%
Max EPS beat(2)18.66%
EPS beat(4)2
Avg EPS beat(4)2.21%
Min EPS beat(4)-18.51%
Max EPS beat(4)18.66%
EPS beat(8)6
Avg EPS beat(8)6.39%
EPS beat(12)8
Avg EPS beat(12)3.21%
EPS beat(16)10
Avg EPS beat(16)0.25%
Revenue beat(2)0
Avg Revenue beat(2)-34.5%
Min Revenue beat(2)-45.8%
Max Revenue beat(2)-23.21%
Revenue beat(4)1
Avg Revenue beat(4)-28.57%
Min Revenue beat(4)-82.22%
Max Revenue beat(4)36.95%
Revenue beat(8)5
Avg Revenue beat(8)-3.68%
Revenue beat(12)7
Avg Revenue beat(12)-3.62%
Revenue beat(16)11
Avg Revenue beat(16)19.41%
PT rev (1m)0.48%
PT rev (3m)1.61%
EPS NQ rev (1m)0.25%
EPS NQ rev (3m)5.33%
EPS NY rev (1m)1.69%
EPS NY rev (3m)4.75%
Revenue NQ rev (1m)1.54%
Revenue NQ rev (3m)-8.37%
Revenue NY rev (1m)-16.23%
Revenue NY rev (3m)-17.93%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 375.25 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.53 | ||
| P/tB | 2.53 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.88
EYN/A
EPS(NY)-3.2
Fwd EYN/A
FCF(TTM)-1.58
FCFYN/A
OCF(TTM)-1.55
OCFYN/A
SpS0.08
BVpS12.6
TBVpS12.6
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.09% | ||
| ROE | -18.66% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-29.53%
ROA(5y)-25.48%
ROE(3y)-34.47%
ROE(5y)-30.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 151.3% | ||
| Cap/Sales | 39.62% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 17.76 | ||
| Quick Ratio | 17.76 | ||
| Altman-Z | 15.98 |
F-Score4
WACC11.91%
ROIC/WACCN/A
Cap/Depr(3y)329.5%
Cap/Depr(5y)270.33%
Cap/Sales(3y)38.3%
Cap/Sales(5y)28.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.45%
EPS Next Y3.39%
EPS Next 2Y-5.06%
EPS Next 3Y-4.25%
EPS Next 5Y25.06%
Revenue 1Y (TTM)-0.23%
Revenue growth 3Y12.08%
Revenue growth 5Y90.61%
Sales Q2Q%-17.1%
Revenue Next Year-51.7%
Revenue Next 2Y-27.75%
Revenue Next 3Y48.26%
Revenue Next 5Y119.67%
EBIT growth 1Y-46.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-63.78%
EBIT Next 3Y-27.01%
EBIT Next 5YN/A
FCF growth 1Y-48.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.64%
OCF growth 3YN/A
OCF growth 5YN/A